Ray Blanco’s FDA Trader

Ray Blanco’s FDA Trader focuses on medical tech stocks with prices that move based on triggers generally unknown to the market.

It is designed to alert you to breakout moves could ultimately drive huge stock market gains...

So Far So Good on Our First Trade

Yesterday, at around 5 p.m. EST, the Anti-Infective Drugs Advisory Committee voted 12-0 to recommend that the FDA approve dalbavancin for ABSSSI. Congratulations if you bought the stock! This is exactly what we expected to happen, and now it's time to evaluate what our next step is going to be.

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!


Ray Blanco’s FDA Trader

Ray Blanco’s FDA Trader focuses on medical tech stocks with prices that move based on triggers generally unknown to the market. It is designed to alert you to breakout moves in the medical markets that could ultimately drive huge stock market gains. It’s the single best way to connect the dots that link today’s dynamic, innovative medical market.

LoginGet Access

Paul Mampilly

Back when Paul Mampilly was growing up in India, nobody talked about the stock market. Yet as a kid, Paul read voraciously about the Great Crash of 1929 and found it fascinating.

When he turned 18, he came to the United States by himself. Since then, he’s had close to 25 years of investment...

View More By Paul Mampilly

LEARN TO TRADE LIKE A PRO WITH THE SEVEN FIGURE PODCAST! [CLICK HERE]